Effect of short-term iPRO continuous glucose monitoring on hemoglobin A1c levels in clinical practice

• Published in: Diabetes technology & therapeutics Vol. 14; no. 8; p. 654
• Main Authors: Pepper, Gary M, Steinsapir, Jamie, Reynolds, Kathryn
• Format: Journal Article
• Language: English
• Published: United States 01.08.2012
• Subjects: Adult; Aged; Aged, 80 and over; Blood Glucose - metabolism; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - drug therapy; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Female; Florida; Glycated Hemoglobin A - metabolism; Humans; Hypoglycemic Agents - administration & dosage; Insulin - administration & dosage; Insulin Infusion Systems; Male; Middle Aged; Monitoring, Ambulatory - instrumentation; Retrospective Studies; Young Adult
• ISSN: 1557-8593
• DOI: 10.1089/dia.2012.0030

This study determined if short-term (professional) blinded continuous glucose monitoring (CGM) improves hemoglobin A1c levels in a mixed group of patients with type 1 and type 2 diabetes in the clinical setting of an office practice. This was a retrospective analysis of 102 consecutive patients with diabetes over the course of 10 months in a subspecialty practice undergoing 3-day blinded CGM using the iPRO(™) device (Medtronic, Northridge, CA). Hemoglobin A1c levels were measured prior to and up to 7 months after the CGM procedure. Before blinded CGM the average hemoglobin A1c level was 7.7±1.0%, and after it was 7.8±1.1%. These values are not statistically different. A subgroup analysis of subjects using continuous subcutaneous insulin infusion treatment also failed to show a significant hemoglobin A1c difference pre- and post-CGM. Using the iPro device for short-term (professional) blinded CGM in an office setting to improve hemoglobin A1c levels may not be a feasible goal for patients with type 1 and type 2 diabetes. The expectations of benefit, choice of patient, and choice of technology for short-term CGM are factors requiring careful consideration before testing takes place.